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SUMMARY – Diabetes is one of the leading public health problems worldwide. Diabetic macular 
edema (DME) is the main cause of vision loss in patients with diabetes. Ideal metabolic control of 
diabetes is the primary goal of treatment and the basic way of preventing and stopping the progression 
of DME. Although laser photocoagulation has been the standard treatment of DME for nearly three 
decades, superior outcomes can be achieved with novel, intravitreal anti-VEGF and steroid therapy. 
Novel treatment option for DME depends on visual acuity and location/extent of macular thickening 
based on optical coherence tomography scans. According to the International Clinical Classifi cation 
Scale, DME is divided into no center-involving DME and center-involving DME (CI-DME). New 
guidelines recommend intravitreal treatment as the treatment of choice for patients with CI-DME 
and moderate visual impairment. Patients with no CI-DME and mild visual impairment should be 
treated with modifi ed ETDRS laser photocoagulation and closely observed. Vitrectomy is the treat-
ment of choice for patients with a tractional component of DME. Nowadays, traditional treatment 
goal of preventing blindness in patients with DME has been changed by the new goal aiming to 
 restore impaired vision, prevent further vision loss and improve visual function. Th erefore, many trials 
addressing this new concept have been underway worldwide.
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Introduction
Diabetes is the most common endocrine disease in 
developed countries and one of the most common 
non-communicable diseases globally, estimated to 
have aff ected more than 415 million people in 2015 
and projected to aff ect 642 million by 20401. Th e exist-
ing burden of disease, high prevalence and incidence, 
life course characterized by development of chronic 
complications, decreased quality of life and increased 
cost of health care make diabetes one of the leading 
public health problems worldwide. Diabetes deaths 
have almost doubled in the last two decades world-
wide2. In 2012, diabetes directly caused 1.5 million 
deaths3, while as much as 5 million deaths were attrib-
utable to diabetes, accounting for 14.5% of global all-
cause mortality among adults1. High blood glucose is 
the 3rd most important risk factor for premature mor-
tality4, and diabetes is the 9th leading cause of disability 
worldwide5. In the last decades, one of the greatest in-
creases in years lived with disability (YLDs) was ob-
served in diabetes, especially in diabetes complications, 
among which the highest increase of 36.7% was ob-
served for vision loss due to diabetes5. In diabetes, vi-
sion loss is most commonly the result of diabetic reti-
nopathy (DR) and diabetic macular edema (DME)6, 
frequent diabetes complications present in as much as 
34.6% and 6.81% of patients with diabetes, respective-
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ly. DME, but not DR per se, is nowadays the main 
cause of vision loss in patients with diabetes7. Al-
though estimations may diff er upon the diagnostics 
used8, studies revealed up to 21 million DME and 28 
million vision threatening DR7.
Diabetic macular edema is a special form of dia-
betic retinopathy, a highly specifi c microvascular com-
plication of diabetes on the eyes. DME is thickening 
of the retina within two diameters of the optic nerve 
from the center of the macula, functionally the most 
important part of the eye9. It is caused by breakdown 
of the blood-retinal barrier, abnormal microvascular 
permeability and consequent leakage of fl uid and plas-
ma constituents into the layers of  the macula10. Struc-
tural changes of DME are characterized by the accu-
mulation of liquid and hard exudates in the outer 
plexiform and inner nuclear layers of the macula and 
formation of fl uid-fi lled cystoid spaces.
Morphologically, macular edema may be focal and 
diff use. Focal edema is well-circumscribed macular 
thickening associated with complete or incomplete 
rings of hard exudates caused by leakage from one or 
more individual microaneurysms. Diff use edema is 
diff use macular thickening caused by widespread leak-
age from dilated and abnormally permeable capillaries. 
Unlike focal edema, diff use edema is less surrounded 
by hard lipid exudates, but more often due to wide-
spread leakage by marked damage to macular architec-
ture and development of cystoid spaces. Especially 
signifi cant edema, because of its impact on the central 
vision, is edema located within 500 μm of the center of 
the macula (clinically signifi cant macular edema).
Risk Factors for DME
Diabetic macular edema develops and progresses as 
a result of the interaction of diff erent non-modifi able 
and modifi able risk factors.
Diabetes duration is the most important non-mod-
ifi able risk factor directly associated with the incidence 
and prevalence of DME in patients with both types of 
diabetes. Th e Wisconsin Epidemiologic Study of Dia-
betic Retinopathy (WESDR) in the USA found that 
20% of patients with type 1 diabetes and 14%-25% of 
patients with type 2 diabetes developed DME over a 
10-year follow up period11. Data from the 25-year fol-
low up of the WESDR cohort found that the cumula-
tive incidence of DME was 29%12,13. Although the cu-
mulative incidence of DME increased with duration 
of diabetes, the correlation was not linear, presumably 
due to the increased competing risk of death.
Hyperglycemia is the strongest modifi able risk fac-
tor for the development and progression of DR and 
DME. Th e Diabetes Control and Complications Trial 
(DCCT) in type 1 diabetes and the United Kingdom 
Prospective Diabetes Study (UKPDS) in type 2 dia-
betes found that tighter control of glycemia (HbA1c 
≤7%) signifi cantly reduced the risk of development 
and progression of DR, DME, vitreal hemorrhage and 
need for laser treatment, as well as the risk of blind-
ness14,15. Th e DCCT also found that intensive glyce-
mic control was associated with 46% reduction in the 
incidence of DME at the end of the trial and 58% 
 reduction 4 years later compared with those in the 
conventional group16.
Hypertension is also an important modifi able risk 
factor for DME12,13. Each 10-mm Hg increase in sys-
tolic blood pressure was associated with an approxi-
mately 15% additional risk of DME17. In the UKPDS, 
patients with hypertension with tight blood pressure 
control had a 34% reduction in the rate of progression 
of DME and 47% reduction in deterioration of visual 
acuity (VA)18. Some clinical trials also showed that 
specifi c blood pressure-lowering medications that tar-
get the renin-angiotensin system had additional ben-
efi cial eff ects on DR and DME, independently of their 
hypotensive actions19,20.
Dyslipidemia has a signifi cant role in the patho-
genesis of DME; some studies report that serum lipids 
were independently associated with DME21. Th e Fe-
nofi brate Intervention and Event Lowering in Dia-
betes (FIELD) study showed that fenofi brate reduced 
the frequency of laser treatment for DME by 31% in 
type 2 diabetes22. Notably, the fi nding in the FIELD 
study appeared not only to be attributable to measur-
able changes in lipid profi le, suggesting that other as 
yet unknown mechanisms could contribute to the pro-
tective eff ect of fenofi brate22.
Other non-modifi able and modifi able risk factors 
are puberty, pregnancy, genetic factors, nephropathy, 
obesity23 and smoking.
Traditional Treatment of DME
Ideal metabolic control of diabetes, assuming strict 
control of well-known modifi able risk factors of hy-
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perglycemia, hypertension, dyslipidemia and others, 
is the primary goal of treatment and the basic way 
of preventing and stopping the progression of 
DME14,15,22,24,25.
Laser photocoagulation has been the primary 
treatment for DME since the early 1980s. Th e role of 
laser in preventing visual loss and blindness due to 
DME was established in 1970s-1980s by two large 
studies, the Diabetic Retinopathy Study (DRS)26 and 
the Early Treatment Diabetic Retinopathy Study 
(ETDRS)27,28. Laser photocoagulation was performed 
as focal treatment of microaneurysms and other areas 
of focal leakage with a 50-100 μm spot size to obtain 
defi nite whitening around the area of leakage, or as 
grid treatment of abnormally permeable capillaries 
and other areas of diff use leakage within two disc di-
ameters of the center using spot sizes of 50-200 μm 
and a space of one burn width apart. Th e ETDRS 
demonstrated that photocoagulation reduced the risk 
of moderate vision loss caused by DME in about 50% 
of the eyes, in only 3% of eyes this therapy led to im-
provement of VA, and in the rest VA unfortunately 
remained poor due to persistence of macular edema27,28. 
Th e ETDRS also indicated that laser treatment was 
neither ideal therapy nor possible in every single eye 
with DME. Th e potential complications of macular 
laser include laser scar expansion, paracentral scoto-
mata, elevation of central visual fi eld thresholds, sec-
ondary choroidal neovascularization and subretinal fi -
brosis29,30.
Novel Treatment Options for DME
Nowadays, the DRCR Network group recom-
mends a modifi ed ETDRS focal/grid laser regimen as 
follows: all leaking microaneurysms 500 to 3000 μm 
from fovea should be treated directly with 50 μm spot 
size, duration 0.05-0.1 s and intensity to achieve gray-
ish reaction; grid treatment should be performed to 
areas of retinal thickening from 500 to 3000 μm supe-
riorly and inferiorly and to 3500 μm temporally with a 
space of two burns width apart31.
Subthreshold micropulse diode laser photocoagu-
lation is a treatment that theoretically avoids damag-
ing the inner neurosensory retina, thereby reducing 
potential complications such as paracentral scotomata 
and enlargement of post-treatment scars. Th is tech-
nique was fi rst described in the late 1990s and since 
then there has been some randomized controlled trials 
(RCTs) comparing this technique to modifi ed ET-
DRS laser treatment32,33. In their trial, Vujosevic et al. 
found improvement of central retinal sensitivity in the 
micropulse group, but its deterioration in the modifi ed 
ETDRS group34. Micropulse laser thus may off er a 
new, less aggressive laser approach in the treatment of 
clinically signifi cant macular edema.
Corticosteroids are potent anti-infl ammatory agents 
that can counteract many of the pathological processes 
thought to play a role in the development of macular 
edema. Th ey prevent leukocyte migration, reduce fi -
brin deposition, stabilize endothelial cell tight junc-
tions, and inhibit synthesis of vascular endothelial 
growth factor (VEGF), prostaglandins and proinfl am-
matory cytokines35,36. Th e fi rst reports on the use of 
intravitreal corticosteroid injection for DME were 
published in 2001-200237,38, suggesting that intravit-
real triamcinolone (IVTA) is potentially an eff ective 
treatment for DME. Th is treatment has gained wide-
spread use as an off -label agent in a number of ocular 
diseases, including DME, most commonly at a dose of 
4 mg of triamcinolone acetonide (Kenalog®; Bristol-
Myers Squibb, Princeton, NJ, USA), despite the lack 
of data from a controlled study demonstrating its safe-
ty and effi  cacy. Recently, the DRCR.net found that 
IVTA had best eff ect on VA improvement within 4 
months of the application and that this eff ect was 
transient39. A longer-lasting and doubling eff ect on VA 
was achieved only by using the IVTA plus focal/grid 
laser treatment40. Th e IVTA treatment is considerably 
limited by adverse events, high incidence of cataract 
formation and raised intraocular pressure40, and diffi  -
culty in delivering eff ective doses of therapeutic agents 
into the vitreous cavity. In recent years, development of 
a sustained-release intravitreal dexamethasone implant 
(Ozurdex®, Allergan Inc., Irvine, CA, USA) has al-
lowed more controlled delivery of the drug with a po-
tentially lower rate of adverse events41. In a study eval-
uating the safety and effi  cacy of dexamethasone im-
plant versus observation in the eyes with persistent 
DME, treatment with intravitreal dexamethasone im-
plant was well-tolerated and produced signifi cant im-
provements in VA, central retinal thickness (CRT) 
and fl uorescein leakage compared with observation42. 
In 2014, the US Food and Drug Administration 
(FDA) approved Ozurdex (dexamethasone intravitreal 
implant) for use in adult patients with DME who have 
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an artifi cial lens implant or are scheduled for cataract 
surgery. Th is makes Ozurdex the fi rst corticosteroid 
approved for use in certain DME patients.
Another novel treatment approach, available for 
less than a decade, is the use of intravitreal therapies 
targeting vascular endothelial grown factor (VEGF)43, 
the most potent known promoter of vascular permea-
bility44. Clinical studies have established that VEGF 
levels are elevated in eyes with DME45 and preclinical 
studies found correlation between increased VEGF 
level and the breakdown of the blood-retinal barrier46. 
Several mechanisms are believed to underlie these ac-
tions, i.e. VEGF directly acts on the permeability of 
intact blood vessels and promotes infl ux of infl amma-
tory cells, thus leading to endothelial cell apoptosis in 
retinal vasculature47. Four VEGF-binding agents are 
currently used for ocular diseases: pegaptanib, bevaci-
zumab (off -label), ranibizumab and afl ibercept.
Pegaptanib (Macugen®; Eyetech Pharmaceuticals, 
Inc. and Pfi zer Inc., New York, USA) is a pegylated 
aptamer that targets the VEGF165 isoform. In 2004, it 
was approved by the FDA for the treatment of wet 
age-related macular degeneration and was the fi rst 
anti-VEGF agent reported to have effi  cacy in the 
treatment of DME. Th e Macugen Diabetic Retinopa-
thy Study Group conducted a phase II RCT of pegap-
tanib for fovea-involving DME48. Th e pegaptanib-
treated eyes had better VA, greater reduction in CRT 
and less need for laser compared to the sham group. 
More recently, data from phase II/III RCT showed 
that pegaptanib was associated with improved VA in 
patients with DME for up to 2 years49. However, Pfi z-
er pharmaceuticals are no longer pursuing further 
studies of pegaptanib in DME.
Bevacizumab (Avastin®; Genentech, South San 
Francisco, CA, USA) is a full-length humanized 
monoclonal G1 antibody that inactivates all VEGF 
isoforms and is indicated for systemic use as an ad-
junct cancer chemotherapeutic agent50. In ophthal-
mology, bevacizumab has emerged as a therapeutic 
agent for retinal vascular diseases51 and has been used 
as an off -label agent in a number of ocular diseases, 
including DR and DME52. Th ere have been a number 
of published trials with short follow up and using dif-
ferent treatment doses/regimens and diff erent com-
parison groups that investigated the eff ect of bevaci-
zumab in DME53. Th e BOLT study compared intra-
vitreal bevacizumab to focal laser and found superior 
VA results at 12 months (+8 vs. -0.5 letters), 5.1 times 
greater odds of gaining >10 letters, and a decrease in 
CRT (130 μm vs. 68 μm) in bevacizumab versus laser 
group54. Ranibizumab (Lucentis®; Genentech, South 
San Francisco, CA, USA) is a humanized antibody 
fragment directed at all isoforms of VEGF-A and is 
fabricated specifi cally for intravitreal use. FDA ap-
proved ranibizumab for the treatment of DME in 
2012 and for the treatment of DR in February 2015. 
Evidence for DME treatment with ranibizumab is 
based on data from phase II and III RTCs, including 
the Safety and Effi  cacy of Ranibizumab in DME 
(RESOLVE)55; Ranibizumab for Edema of the mAc-
ula in Diabetes (READ-2)56; Core Study to Assess the 
Effi  cacy and Safety of Ranibizumab Intravitreal Injec-
tions (RESTORE)57; Diabetic Retinopathy Clinical 
Research Network (DRCR.net) Protocol I58 and 
Study of Ranibizumab Injection in Subjects with CS-
DME Secondary to Diabetes (RISE and RIDE)59.
Afl ibercept (Eylea®; Bayer Healthcare Pharma-
ceuticals, Berlin, Germany) is a 115-kDA recombi-
nant fusion protein consisting of the VEGF binding 
domains of human VEGF receptors 1 and 2 fused to 
the Fc domain of human immunoglobulin-G160. Ani-
mal studies demonstrated intravitreal afl ibercept to 
have theoretic advantages over bevacizumab and ra-
nibizumab, including longer half-life in the eye and 
higher binding affi  nity to VEGF-A61. In addition, the 
fusion protein binds PGF 1 and 2, which have been 
shown to contribute to excessive vascular permeability 
and retinal neovascularization62. In 2014, FDA ap-
proved afl ibercept for the treatment of DME and in 
March 2015 for the treatment of DR in patients with 
DME. Evidence for DME treatment with afl ibercept 
is based on data from phase II and III RCTs, including 
the DME and VEGF Trap-Eye: INvestigation of 
Clinical Impact (DA VINCI) study63; Study of VEGF 
Trap-Eye in Vision Impairment due to DME (VIV-
IDDME) and Intravitreal Administration of VEGF 
Trap-Eye in Patients with DME (VISTADME)64. More 
recently, data from the DRCR.net Protocol T showed 
that intravitreal afl ibercept, bevacizumab and ranibi-
zumab improved vision in eyes with center-involved 
DME, but the relative eff ect depended on baseline VA. 
When the initial VA loss was mild, there were no dif-
ferences among study groups. At worse levels of initial 
VA, afl ibercept was more eff ective in improving vi-
sion65.
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All intravitreal anti-VEGF agents were generally 
well tolerated in all studies. Th e most commonly re-
ported ocular serious adverse events were endophthal-
mitis and increased intraocular pressure. Systemic ad-
verse events in patients having received anti-VEGF 
for DME occurred at rates equal to those in patients 
that received laser treatment or sham injection. Th e in-
cidence of cardiovascular events and arterial thrombo-
embolism reported in these studies was low, possibly 
because high-risk patients were excluded.
Surgical vitrectomy as a novel treatment of DME 
is indicated in widespread/diff use DME that is refrac-
tory to laser and intravitreal treatment, and is caused 
by vitreous traction in association with visual impair-
ment. In their study of vitrectomy for DME, Haller et 
al. found improvement of VA by ≥10 letters in 38%, 
reduction in central subfi eld thickness to <250 μm in 
50% of patients, and reduction of thickness of ≥50% in 
most of the eyes66.
Guidelines for Treatment of DME
Treatment of DME depends on VA and location/
extent of macular thickening based on optical coher-
ence tomography (OCT) scans, and the guidelines 
provide paradigms based on the classifi cation scale, 
current evidence and consensus of opinion67-69. Ac-
cording to the International Clinical Classifi cation 
Scale, DME is divided into no center-involving DME 
and center-involving DME, confi rmed with OCT, 
which is not explained by thickening from an epireti-
nal membrane70. Visual acuity 6/9 (0.7) and OCT cen-
tral subfi eld thickness >250 μm are crucial when 
choosing a treatment option, also referring to the pa-
tient’s individual circumstances.
No center-involving DME should be treated with a 
modifi ed ETDRS focal/grid laser photocoagulation 
according to the following recommendations31:
 – direct focal photocoagulation of leaking micro-
aneurysms 500 to 3000 μm from fovea with 50-
μm spot size, duration 0.05-0.1 s and intensity 
to achieve grayish reaction, and
 – grid photocoagulation of areas of retinal thick-
ening from 500 to 3000 μm superiorly and infe-
riorly and to 3500 μm temporally with barely 
visible 200-300 burns size 50-100 μm, duration 
0.05-0.1 s and a space of two burns width apart.
Th e same treatment should be considered in cen-
ter-involving DME with VA >6/9 (0.7), central sub-
fi eld thickness <250 μm and microaneurysms located 
in areas accessible to laser. After the macular laser, 
3- to 4-month follow up is recommended as long as no 
other features are present that require other treatment 
option or more regular follow up.
Center-involving DME with VA >6/9 (0.7) and 
central subfi eld thickness >250 μm should be treated 
with intravitreal anti-VEGF agents with or without 
macular laser. For phakic eyes unresponsive to these 
treatments, intravitreal dexamethasone implant may 
be considered, bearing in mind the potential side ef-
fects. Th e same treatment should be undertaken in 
center-involving DME with VA 6/9-6/10 (0.7 to 0.6) 
or worse and central subfi eld thickness >250 μm. For 
pseudophakic eyes, IVTA or dexamethasone implant 
with or without laser may also be considered. Anti-
VEGF treatment regimen includes initial loading 
phase of monthly injections for 4-6 months, followed 
by PRN phase with continued treatment until the 
macula is dry or until there is no further improvement. 
Monthly follow up of patients undergoing anti-VEGF 
treatment with VA assessment and OCT scan is re-
quired to decide on re-treatments. For patients under-
going intravitreal steroid treatment, regular monitor-
ing of intraocular pressure is also required. If the pa-
tient has been stable off  treatment for several monthly 
assessments, the period between follow up appoint-
ments may be increased gradually to a maximum of 
3-4 months as long as there are no other features re-
quiring more frequent follow up. Center-involving 
DME with VA <6/12 (0.5) and central subfi eld thick-
ness >250 μm should be observed, especially if long-
standing and no response to previous laser, or if there 
is huge macular ischemia. Otherwise, anti-VEGF or 
steroid treatment may be considered after careful con-
sultation. Center-involving DME with vitreomacular 
traction is an indication for vitrectomy with or without 
intravitreal anti-VEGF or steroid treatment.
Conclusion
Diabetic macular edema is a signifi cant public 
health challenge. Many patients are undiagnosed and 
untreated, and even those treated with standard laser 
therapy may respond poorly and progressively lose vi-
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sion. Although laser photocoagulation has long been 
the primary treatment for preventing blindness in pa-
tients with DME, treatment goals should now aim to 
restore impaired vision, prevent further vision loss and 
improve visual function. Better knowledge of the 
pathophysiology of DME and recent RCTs suggest 
that these goals can be achieved using novel treatment 
options, intravitreal anti-VEGF and corticosteroid-
based therapy, with a well-documented tolerable safety 
profi le. As a result of these recent data, the intravitreal 
anti-VEGF agents and steroids are suggested as fi rst-
line treatment in place of laser photocoagulation in 
DME causing vision loss. New guidelines recommend 
intravitreal treatment as the treatment of choice for 
patients with center-involving DME and moderate 
visual impairment. Patients with no center-involving 
DME and mild visual impairment should be treated 
with modifi ed ETDRS focal/grid laser photocoagula-
tion and closely observed. Vitrectomy is the treatment 
of choice for patients with a tractional component of 
DME. Undoubtedly, in the future patients might need 
various combinations of these therapies to obtain the 
best outcome; thus, many studies are already running 
to address this goal.
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Sažetak
DIJABETIČKI MAKULARNI EDEM: TRADICIONALNI I NOVI PRISTUP LIJEČENJU
M. Tomić, R. Vrabec, T. Poljičanin, S. Ljubić i L. Duvnjak
Dijabetes je jedan od vodećih svjetskih javnozdravstvenih problema. Dijabetički makularni edem (DME) je glavni uzrok 
sljepoće u osoba oboljelih od dijabetesa. Idealna metabolička regulacija bolesti je primarni cilj liječenja i osnovni način sprje-
čavanja i zaustavljanja progresije DME-a. Iako je laserska fotokoagulacija u posljednja tri desetljeća smatrana standardnim 
načinom liječenja DME-a, bolji ishod moguće je postići primjenom nove intravitrealne anti-VEGF ili steroidne terapije. 
Novi pristup liječenju DME-a ovisi o vidnoj oštrini i smještaju/veličini makularnog zadebljanja utvrđenog optičkom kohe-
rentnom tomografi jom. Prema Međunarodnoj kliničkoj klasifi kaciji DME se dijeli na DME koji ne zahvaća centar makule 
(ne CI-DME) i DME sa zahvaćenim centrom (CI-DME). Nove smjernice preporučuju intravitrealno liječenje kao prvi 
izbor liječenja za bolesnike s CI-DME i umjerenim padom vidne oštrine, dok bolesnike s ne CI-DME i blagim padom 
vidne oštrine treba liječiti modifi ciranom ETDRS laserskom fotokoagulacijom i pažljivo pratiti. Operativni zahvat vitrekto-
mija izbor je liječenja bolesnika s trakcijski izazvanim DME-om. U današnje vrijeme je sprječavanje sljepoće kao tradicional-
ni cilj liječenja DME-a zamijenjen novim ciljevima, a to su oporavak oštećene vidne oštrine, sprječavanje daljnjeg slabljenja 
vida i poboljšanje vidne funkcije pa se danas u tu svrhu provode brojna znanstvena i klinička istraživanja širom svijeta.
Ključne riječi: Dijabetes melitus; Makularni edem; Laserska fotokoagulacija; Vitrektomija
